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Adrian Thorogood
Abstract
Improving our understanding of rare disease and developing new therapies 
can only succeed through global collaboration. Whole genome sequencing is 
increasingly being deployed to diagnose rare disease, and can be combined with 
machine-learning tools that analyze patient photos to identify phenotypes. Clinical 
interpretation of genomes and phenotypic data in rare disease depends on shar-
ing individual patient data internationally. Data sharing is essential in rare disease 
contexts, to support the diagnosis of patients, recruitment into trials, the develop-
ment of precision diagnostics and therapies, and clinical trial transparency. The 
sharing of rich molecular and phenotypic data presents privacy risks for rare disease 
patients, though many want to see their data made available to improve their care 
and advance research. Informed consent, access governance, and access technolo-
gies are important to realize the benefits of data sharing while mitigating risks. 
Rare disease patients should be involved in the design of data sharing governance to 
ensure it responds to their particular needs and preferences.
Keywords: rare disease, data sharing, law, ethics, consent, privacy, patient 
involvement
1. Introduction
There is great interest in adopting data-intensive approaches as part of both care 
pathways and research in rare disease contexts. Indeed, many rare diseases “have no 
treatments, are incurable, and have a devastating impact on patients and their fami-
lies” [1]. One of the first areas where whole-genome sequencing is already dem-
onstrating clinical utility is in helping to provide a genetic diagnosis of individuals 
with rare disease [2]. Whole-genome sequencing can be a powerful tool to resolve 
diagnoses for patients with rare disease. Receiving a timely and accurate diagnosis 
can have a number of direct benefits for patients, “enabling a better understanding 
of their prognosis, more personalized treatment and tailored management and sur-
veillance” [3]. An ethics report from Canada’s health technology assessment body, 
CADTH, recently concluded that genome sequencing could be effective for patients 
with unexplained developmental disabilities and multiple congenital abnormalities, 
if responsibly administered [4].
Data-intensive medicine is powered by data sharing. Data sharing practice and 
policy has long been a hallmark of genomic research. Many health research funders 
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and journals now require researchers to deposit sequence data in repositories or 
otherwise make data available to the broader research community. “Data sharing 
enables researchers to rigorously test the validity of research findings, strengthen 
analyses through combined datasets, reuse hard-to-generate data, and explore new 
frontiers of discovery” [5]. Data sharing in health care contexts is also growing in 
importance. The American College of Medical Genetics and Genomics (ACMG), for 
example, “advocates for extensive sharing of laboratory and clinical data from indi-
viduals who have undergone genomic testing” [6]. Data sharing is expected to have 
a range of benefits, including improving the diagnoses of other patients, informing 
the development of diagnostic approaches and tools, and powering research. Some 
have even argued that sharing minimal information about variant interpretations 
should be the standard of care in genetics [7].
Data sharing is of particular importance in rare disease contexts. Making a diag-
nosis is often dependent on many forms of data sharing. Databases of population 
genetic variation are needed as a reference to help filter out benign variants from 
test results. Comparison of family trios can help filter candidate disease-causing 
variants even further. Making a genetic diagnosis available through publications or 
public genetic variant databases can offer confirmation and can inform and accel-
erate the diagnosis of future patients. Data-intensive approaches are not limited 
to genomic data. Facial recognition technologies such as Face2Gene can inform 
diagnosis based on images of facial morphology [8]. Because the meaning of all this 
data is not fully understood, data-intensive medicine for rare disease depends on 
adoption of a learning health system approach. In learning health systems, rich data 
are generated as part of routine clinical care and are subsequently made available 
for quality improvement and research. Data sharing between rare disease clinicians, 
laboratories and scientists can help to refine interpretive techniques and analysis 
pipelines. Images and videos of facial morphology can be used to train machine-
learning algorithms and improve diagnostic tools [9].
The impetus to make genomic and health-related data collected as part of rou-
tine clinical care available for research is stronger in the rare disease context, where 
there are numerous barriers and limited incentives. These data could also serve as 
a rich resource for natural history studies to better understand the progression of 
rare diseases, for biomarker discovery, as registries to recruit patients into precision 
clinical trials, and as a resource for ongoing surveillance of the clinical and cost 
effectiveness of rare disease therapies.
Biobanking and biobank networks are essential infrastructure for genomic 
research, which require collection and analysis of biospecimens [10]. Biobanks are 
organized collections of samples and associated data. Samples have to be collected, 
stored, and shared following scientific and technical standards in order to be 
comparable. Biobanks must meet standards of quality and size to be scientifically 
valuable. Biobank networks are established to enable aggregation of samples and 
data from geographically disperse patients. This is essential in the rare disease 
context. Fostering standardization is a complicated challenge for biobank networks. 
In the era of Big Data, the value of biobanks increasingly lies in their datafication. 
Datafication includes: (1) the collection of rich associated demographic, health 
and clinical information about patients, and (2) the analysis of samples to generate 
molecular, imaging or other forms of biological data. Of course, the quality and 
compatibility of data collected or generated is also essential to aggregation of data 
across biobank networks. In order to attract researchers and additional resources 
to understudied areas like rare disease, biobank networks and datafication are key. 
This article will focus primarily on data sharing, but the reader should keep in mind 
that the generation of data from biological samples is an essential step, one that is 
organizationally and scientifically non-trivial.
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Little will be achieved for rare disease patients without collaboration and inter-
national data sharing. No single institution, laboratory, or even country is likely to 
encounter a sufficient number and diversity of patients with a given rare disease to be 
able to advance research alone. In the next section, I review some major data-driven 
initiatives to improve rare disease care and research. These learning health system 
approaches, powered by international data sharing, are essential to deliver data-
intensive medicine for rare disease. International data sharing does raise concerns 
about the privacy of patients with rare disease. I discuss issues of privacy and consent 
in data-intensive rare disease medicine and research. However, it is important to 
note that many rare disease patients want to make their data available to improve 
their care and to support research. It is therefore important that patients are involved 
in the development and implementation of data sharing governance to ensure the 
benefits of data sharing are achieved while managing risks to patient privacy.
2. Rare disease data sharing initiatives
This section discusses the importance of data sharing for rare disease, across the 
research lifecycle, from diagnosis and basic research, to clinical trial transparency, 
to health technology assessment.
2.1 Diagnosis and drug discovery
A number of national and international initiatives have emerged to demonstrate 
the potential of data to improve rare disease patient care and to accelerate research. 
All of these initiatives seek to adopt data-intensive approaches to accelerate rare 
disease diagnosis. They adopt learning health system strategies, which involve col-
lecting rich data as part of routine clinical care and making these data available for 
research to improve diagnostics and therapies. Finally, the initiatives all recognize 
the importance of international data sharing in the rare disease context.
The Genomics England 100,000 Genomes Project has “committed to sequenc-
ing 100,000 whole human genomes, from 70,000 patients, by the end of 2018” 
[11], with a focus on rare and infectious diseases [12]. This project will facilitate the 
introduction of genomic medicine in NHS care while contributing to the personal-
ization of its medicine [11]. Clinicians are hoping to achieve earlier diagnoses and 
develop more effective treatments with this data [13]. Researchers also hope to gain 
a better understanding of cancer.
Genome Canada has proposed a national, clinical genomics project, which aims 
to advance precision medicine for all Canadians, with an initial pilot focused on rare 
disease [14]. The proposal is to introduce genomic testing as part of clinical care. 
The data will then be made available as a research platform. The vision is to establish 
a national cohort, perhaps through a federation of provincial datasets.
The European Joint Program on Rare Diseases (EJP RD) brings 130 institutions 
together across 27 EU Member States as well as Canada, Armenia, Georgia, Israel, 
Norway, Serbia, Switzerland and Turkey, to accomplish its two main goals: [15].
1. “To improve the integration, the efficacy, the production and the social 
 impact of research on [rare disease] through the development, demonstration 
and promotion of Europe/world-wide sharing of research and clinical data, 
materials, processes, knowledge and know-how
2. To implement and further develop an efficient model of financial support for 
all types of research on [rare disease] (fundamental, clinical,  epidemiological, 
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social, economic, health service) coupled with accelerated exploitation of 
research results for benefit of patients” [15].
To achieve its objectives, the EJP-RD has developed a five pillars structure 
subdivided in various themes and activities such as Joint Transnational Calls for col-
laborative research projects; a common virtual platform for discoverable data and 
resources for rare disease research; capacity building and training of patients and 
researchers in rare disease research and processes, all to accelerate the validation, 
use and development of innovative methodologies tailored for clinical trials in rare 
diseases [15].
Through the Breaking Barriers to Health Data Project, the World Economic 
Forum is “partnering with genomics institutes in the United Kingdom, the United 
States, Canada and Australia” [16] to pilot a governance framework “to support 
the effective and responsible use of federated data systems to advance rare disease 
diagnostic and treatment-related research” [16]. Federated data systems enable 
researchers to query a distributed network of secure databases. The individual-
patient data remains hidden in each of the secure nodes. This pilot project aims to 
demonstrate a proof-of-concept for federated data systems, accompanied with an 
economic analysis and a scalable governance framework [16].
An example of a commercial initiative to overcome the geographic barriers to 
rare disease research is the start-up RDMD [17]. This company aims to generate a 
rich, regulatory-grade biobank, database, and registry of patients with rare disease 
from across the United States (US) and internationally. The start-up leverages the 
rights of patients in the US and in other countries to request access to their health 
records and biospecimens for onward transfer to RDMD. RDMD then looks to enter 
into partnerships with pharmaceutical companies to accelerate their research into 
rare disease therapies. Patients are provided with access to their aggregated and 
structured medical record through an app.
2.2 Clinical trial transparency
Improving the transparency of clinical trials has been an important public 
health priority for regulators and policy-makers in recent years. Clinical trial 
transparency encompasses the registration of clinical trials before recruitment, the 
timely dissemination of results—whether positive or negative, and the sharing of 
individual patient data supporting those results [18]. Sharing of individual patient 
data enables reproducibility studies to confirm the validity of results, and facilitates 
meta-analyses. Transparency can also accelerate research and reduce duplicative 
trials that waste resources and expose participants to unnecessary risks. Regulators 
increasingly publish the clinical data submitted by pharmaceutical companies 
seeking market approval [19]. Some sponsors also proactively make individual 
patient data available. There are now several data sharing platforms that facilitate 
clinical trial data sharing, including Yale Open Data Access project (YODA) [20], 
ClinicalStudyDataRequest [21], and Vivli [22].
Ensuring that the results of clinical trials as well as the underlying data are 
made available is perhaps more important for rare disease clinical trials. Regulators 
sometimes allow more flexibility and accept greater clinical uncertainty to acceler-
ate approvals of drugs for rare diseases with high unmet need. This is because of 
the “unique challenges that hinder efficient and effective traditional clinical trials, 
including low patient numbers, limited understanding of disease pathology and 
progression, variability in disease presentation, and a lack of established endpoints” 
[1]. Where there is greater uncertainty over the meaning of research data, there is 
a greater need for transparency to support regulators, prescribing physicians, and 
5International Data Sharing and Rare Disease: The Importance of Ethics and Patient Involvement
DOI: http://dx.doi.org/10.5772/intechopen.91237
patients. Sharing individual patient data does raise concerns about patient privacy, 
discussed below. The tension between transparency and privacy, however, tends 
to be overstated, as benefits can be promoted and risks can be reduced through 
governance mechanisms. Moreover, rare disease patients are generally supportive 
of greater transparency, as long as their privacy is protected, appropriate steps are 
taken to seek their consent, and patient groups are involved in the design of data 
sharing governance.
2.3 Access to medicines
Even where approved medicines are available for rare disease, an additional 
hurdle is convincing health technology assessment bodies that these medicines—
which are often very expensive per patient—are cost-effective [23]. There is often 
significant uncertainty over the clinical and economic value offered by rare disease 
therapies, in part because of the limits to generating clinical evidence in small 
patient populations. One potential solution to accelerate patient access is through 
managed access programs. Where countries offer these programs, drugs may be 
given early approval despite some uncertainty over value, under the condition 
of ongoing collection of data to fill in evidentiary gaps. Real world evidence is 
collected through post-market surveillance to confirm the drug delivers value. 
Post-market surveillance, however, is challenging and requires effective data 
sharing strategies and infrastructure. Moreover, it is important to involve patients 
in decisions to approve drugs where there is greater uncertainty over benefits and 
risks. Patient can also be engaged in establishing the conditions under which a drug 
would meet or fail to meet the conditions of a managed access agreement. Indeed, 
patients are increasingly involved in health technology assessment to ensure that the 
drugs are delivering the clinical, economic, and personal value that matters to them 
[24]. Given the diverse burdens of disease on rare disease patients and their caregiv-
ers, they have important perspectives on the true value that can be delivered by new 
therapies.
3. Privacy
Data-intensive medicine, and the research, biobanking, and data sharing that 
necessarily accompany it, all raise privacy concerns for patients. In the Big Data 
era, increasingly rich data are being generated as part of clinical care and research 
protocols. Traditionally, privacy in research was primarily protected by removing or 
separating identifiers from research data. Rich, multi-dimensional health data can 
no longer be definitively de-identified. Genomic data for example is rich, unique to 
the individual, stable over time, and shared across families. It also contains poten-
tially sensitive information about the health predispositions of individuals and 
their families. Genomic data therefore raise particular concerns about the limits of 
de-identification [25]. But the problem is broader than just genomic data. A recent 
study also showed that 99.98% of American can be reidentified from a database 
with less than 15 demographic attributes [26]. Re-identification is increasingly seen 
as an inherent risk in research. This risk increases as the dimensionality of data 
increases, as more publicly available data becomes available, and as new statistical 
re-identification tools emerge. If patients are re-identified, sensitive informa-
tion about their health may be disclosed to unauthorized third parties, including 
employers, insurers, and family members, and may be used to discriminate against 
or stigmatize the individual or their family. Sharing patient data with clinicians and 
researchers around the world may heighten concerns over privacy. Where data are 
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copied and distributed to many different parties, there is a greater potential for a 
breach of confidentiality or security, and lower confidence that the breach will be 
identified and rectified.
Rare disease patients may face a greater risk of re-identification or subsequent 
harm. Rare disease patients may be easier to single-out in a dataset, given their 
unique genotypes and phenotypes, and the small number of participants in a 
study. Rich data is often collected or generated about rare disease patients, such as 
whole genome sequences and pictures and videos of their phenotypes. In order to 
match similar patients to inform a diagnosis, or to conduct a study with an accept-
able sample size, information about rare disease patients must often necessarily 
be shared beyond institutions and national borders. Moreover, in part because of 
institutional and geographical barriers to care and participation in research, many 
rare disease patients share rich health information about themselves online with 
patient support groups or researchers. In fact, there are numerous academic and 
commercial research efforts that enable remote participation of rare disease patients 
to overcome geographic barriers [27]. The public availability of patient information 
could potentially increase the risk of re-identification in research datasets.
At the same time, many patients with rare disease see the important clinical and 
scientific value of data sharing and are willing to participate if research involves 
appropriate consent processes, safeguards, and patient involvement. A number of 
solutions have evolved to reduce the tension between privacy and openness. The 
first solution is to develop more transparent consents about how data are shared. 
This is recommended by the Global Alliance for Genomics and Health (GA4GH) 
Consent Policy [28]. Consent is discussed in greater detail in the next section. The 
second solution is through safeguards and governance, including robust de-identifi-
cation, security protections, and access controls. Responsible data governance aims 
to maximize uses of data that benefit science and society, minimize risks to data 
subjects, and strike a proportionate balance where these interests come into con-
flict [29]. Risks of data breaches or misuse when sharing data can be significantly 
reduced through governance mechanisms including due diligence review of access 
requests by an expert committee, data access agreements that protect participant 
privacy, and ongoing monitoring of data use. Sharing data within secure cloud 
environments can enhance security and accountability by limiting the distribution 
of copies of datasets. Federated network technologies now allow researchers to sub-
mit search queries or run research analyses across multiple secure patient databases, 
without ever having to access the patient results. The World Economic Forum is 
exploring such an approach specifically for international rare disease research (see 
above). A third solution, also discussed below, is greater patient involvement in the 
design or research and data sharing governance, to ensure their input on priorities 
and the balancing of risks and benefits under uncertainty.
There is also a risk of too much privacy protection in the rare disease context. 
Data privacy laws are tightening globally in response to concerns over commercial 
and law enforcement surveillance practices. Europe’s General Data Protection 
Regulation (GDPR) is now in force, and California will soon be introducing its own 
comprehensive consumer data privacy regime [30]. The GDPR imposes stricter, 
more formal procedural and security safeguards for the protection of personal data, 
particularly for special categories of data, for example, health and genetic. It also 
imposes higher consent standards with regards to the purposes of processing, and 
transfers between organizations and across borders. Different national and insti-
tutional interpretations of the GDPR have hampered international health research 
collaborations [31]. Formal legal safeguards and strict transparency requirements 
leave organizations with less flexibility to share samples and data about rare disease 
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patients, especially internationally, even where researchers seek explicit patient 
consent and/or patient involvement in data sharing governance.
4. Consent
This section considers three issues concerning consent in data-intensive medi-
cine for rare disease. The first concern is that it is impossible to fully specify all the 
potential users and uses of patient data at the time of collection. A common solution 
when seeking consent to research and sharing of samples and data is seeking broad 
consent to future not-fully-specified uses accompanied with ongoing governance. A 
second issue is re-use or sharing of legacy collections of samples and data that have 
significant scientific and societal value but where the original consent is absent or 
is silent about key matters. A third issue is consent in the pediatric context, which 
raises special concerns about capacity, protection from harm and exploitation, 
inclusion, and shared decision-making. Arguably, the tension between promoting 
science and respecting individual autonomy is greater in the rare disease context.
4.1 Broad consent
The International Rare Diseases Research Consortium (IRDiRC) in collaboration 
with the GA4GH has shared template consent clauses for rare disease research [32]. 
These clauses emphasize some of the special characteristics of rare disease research, 
such as the collection of photos and videos of patient phenotypes, the participation 
of and feedback of health findings to family members, as well as the imperative 
of international data sharing to support both research as well as to match patients 
to inform diagnoses. This initiative also demonstrates the importance of engaging 
patients in the development of research governance and consents.
Biobanking and data sharing aim to make samples and data available for research 
that cannot be fully specified at the time of recruitment and collection. This present 
risks to patient autonomy: how much information can and should be provided at 
the time of consent? What kinds of meaningful choices can and should be offered to 
patients about who can access their samples and data? As samples and data are typi-
cally stored for long periods of time, can and should patients be able to withdraw 
consent or change their preferences over time? Broad consent—consent to not-
fully-specified research uses coupled with ongoing governance—has been adopted 
in many research contexts internationally, is now expressly permitted under the US 
Common Rule and recognized under the EU GDPR (rec 33) [33].
Especially where samples and data are collected in clinical care contexts, there is 
concern that sharing those samples and data for research may be done coercively, or 
that patients may have limited knowledge or comprehension. Moreover, rare disease 
patients may see data sharing as a necessity for receiving a diagnosis, or to advance 
research on a cure, and thus may feel compelled to forgo their privacy. Where 
consents cover a broad set of purposes, this can be seen as coercively tying purposes 
together, unless patients are given granular choices. But these kinds of arguments 
can result in inefficient sharing and use of data that precludes effective care and 
research, and that contradicts the wishes of many rare disease patients. Broad con-
sent may be especially important in rare disease, given the scarcity of data and the 
risk of losing that data if every subsequent use is subject to re-consent. There is also 
an argument that rare disease data, again considering its scarcity, should be made 
available for a wide range of purposes, including diagnostic matchmaking, research 
to discover new biomarkers, natural history studies to better understand the nature 
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of a rare disease, and the recruitment of individuals into precision medicine clinical 
trials. Generating multiple siloed resources for multiple different purposes is simply 
not feasible.
4.2 Legacy collections
Legacy collections of samples and data are those collected without consent or 
without consent covering core consent elements required to conduct research or 
data sharing. These collections present an ethical dilemma: they often continue to 
have great scientific and societal value if shared and used for research, but the con-
sent to do so is missing or insufficient. This is particularly a problem in biobanking, 
where samples are often collected many years before they are able to be distributed, 
aggregated, or analyzed. As the years pass, scientific and data sharing practices can 
change, and regulatory and ethical frameworks can evolve. As a result, the existing 
consents may become insufficient. One could argue the ethical dilemma is even 
more pressing in rare disease contexts, because of the high unmet need for research 
into novel diagnostics and therapies, as well as the associated practical difficulties 
of recruiting geographically disperse patients and collecting samples.
Solutions have been developed for legacy collections that aim to strike an 
appropriate balance between making them available for research, while also making 
best efforts to communicate with and respect the expectations of patients. When 
seeking to study or share legacy collections, an important starting point is to assess 
the existing consent materials (if applicable) [34]. If core elements of consent 
are met, then the research may be able to proceed. If the consent is silent on the 
desired research or data sharing, then patients should be recontacted to renew their 
consent. If permitted by applicable norms, it may also be sufficient to notify the 
patients and provide them with an opportunity to opt-out. In many cases, however, 
re-consent or re-contact will be impossible if patients can no longer be found. In 
such cases, some jurisdictions allow research ethics committees (RECs) to alter or 
waive consent requirements, as long as certain conditions are met. In Canada for 
example, a consent alteration/waiver is available where research is minimal risk, 
consent is impracticable, the alteration/waiver will not adversely harm individuals, 
there are appropriate safeguards in place, and there has been no clear refusal by the 
individual (art 3.7B (samples); art 5.5A (identifiable information)) [35].
Where consent is silent, an ethics waiver may be more easily justified. Where 
consent makes a specific commitment (e.g., guarantees data will be kept confiden-
tial, or will only be used for a specific research project), it may be harder to justify 
a waiver. Because consent is often take-it-or-leave-it, however, it is not necessarily 
clear if the commitment was determinant to the patient’s decision, or what the 
patient would have preferred. An active refusal by the patient to participate in 
research or data sharing is a more clear-cut case [36]. For example, the patient may 
have been offered the option to participate in research or to share their data and may 
have refused. Indeed, the revised US Common Rule for research on human subjects 
in the US prohibits use of an ethics waiver when a patient has rejected a broad 
consent (§46.116) [37]. Practically, however, given the limits of tracking systems, it 
is unclear how these refusals can be tracked and respected over time.
Typically, ethics waivers are used to approve a specific research project using 
legacy collections, but in some cases, they have also been used to approve the 
deposit of data into international databases for onward sharing. The GA4GH 
recommends ethics waivers under certain conditions for international sharing of 
genomic and health-related data [34].
A final consideration offering some additional flexibility in rare disease contexts 
is patient involvement. Patient groups or representatives may lend moral support 
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to a particular interpretation of an existing consent, or to a particular decision to 
re-use or share legacy collections with an ethics waiver. This can help to alleviate 
uncertainty over what patients would have wanted in cases of uncertainty. If core 
consent elements are legally required, however, such modifications will not be 
possible.
4.3 Consent and capacity: pediatrics
An additional challenge that tends to be overlooked in data sharing discussions is 
that many patients with rare disease are minors, who are generally legally presumed 
to lack the capacity to consent to genetic testing, research participation, or release 
of personal data on their own [38]. Moreover, a number of rare diseases involve 
intellectual disability, which may diminish the decision making capacity of rare 
disease patients. Regulatory frameworks developed in the context of experimental 
research are traditionally protectionist, aiming to ensure vulnerable individuals are 
protected from harm and exploitation. These frameworks place several limitations 
on research involving minors. Where research is allowed, additional safeguards 
must be in place for minors. The guiding legal and ethical principle is the best 
interests of the child, though this principle is somewhat modified in the research 
context. A modified best interests limitation is only allowing research if it offers 
direct benefit to the individual or to individuals with a similar age or condition, 
and that the benefit is favorable vis-a-vis the individual risks, as determined by 
a REC. Where research is permitted, the minor is protected by parental (or legal 
guardian) representation, who must provide informed consent. The parent would 
be provided with detailed information about the research and would be asked to 
consent on behalf of the child.
This protectionist approach has been somewhat modified both by public health 
and human rights concerns. From a public health perspective, the inclusion of 
children in research is imperative to ensuring that the standard of care improves for 
conditions that predominantly affect children. Given the physiological differences 
between children and adults, drugs demonstrated to be safe and effective for adults 
may not be so for children. Human rights instruments and discussions have also 
highlighted the principle of non-discrimination, which argues that some attempts 
to protect children ultimately result in their exclusion from participation in society.
Another important human rights and ethical principle is respect for the devel-
oping autonomy of the child. Mature-minor exceptions address the developing 
capacity of minors to make decisions. These regimes allow exceptions for children 
below the age of majority to make certain their own decisions (e.g., for health care) 
if they demonstrate their capacity to understand information and appreciate the 
consequences of decisions. Regardless of who has ultimate legal capacity to consent, 
children should generally be given appropriate opportunities to be involved in 
decisions concerning them. Many health research ethics guidelines recommend that 
children should be involved in decisions through assent, where the child is provided 
with age appropriate information and asked if they would like to participate, and 
dissent, where a clear objection to participation must also generally be respected 
by researchers. Dissent is more clearly applicable in experimental research, such as 
distress caused by a needle, than in data-intensive research.
Based on the principle of inclusion, as well as practical implications, the GA4GH 
Pediatric Task Team has argued that those who generate pediatric data as part of 
research or clinical care have an obligation to offer minors and their parents an 
opportunity to share their data, so as to benefit the care of children in the future 
[39]. The best interests of the child are ensured in this context through the ben-
efit–risk assessment, ongoing data governance (to maximize scientific and societal 
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benefits while minimizing risk), parental representation and informed consent, 
and the child’s involvement through assent processes.
5. Patient involvement
This section discusses patient involvement (also referred to as patient engage-
ment) in the governance of research, challenges to involving patients effectively 
and responsibly, and how rare disease patients may be involved specifically in the 
governance of biobanking and data sharing.
Respect for communities is an important ethical principle in health research. 
According to Charles Weijer et al. researchers have “an obligation to respect the 
values and interests of the community in research and, wherever possible, to protect 
the community from harm” [40]. This principle is also prominently featured in 
the international health research ethics guidelines of the Council for International 
Organizations of Medical Sciences and World Health Organization: “[r]esearch-
ers, sponsors, health authorities and relevant institutions should engage potential 
participants and communities in a meaningful participatory process that involves 
them in an early and sustained manner in the design, development, implementa-
tion, design of the informed consent process and monitoring of research, and in the 
dissemination of its results” (Guideline 7) [41]. Communities are not only defined 
geographically, but include subpopulations affected by or able to influence research. 
Patients affected by a particular condition are clearly a key stakeholder in related 
research.
The involvement of patients and patient advocacy organizations across the 
research, drug-development, and delivery of care life cycle is increasingly practiced 
and is the subject of numerous national and international research ethics guide-
lines. Patient involvement is when patients “meaningfully and actively collaborate 
in the governance, priority setting, or design and conduct of research” [42]. The 
term patient is understood broadly to include “those having or a risk of having a 
medical condition, their families, and their caregivers” [43]. Patients have intimate, 
lived experience with and understanding of their medical condition, and how 
symptoms affect their everyday lives. These perspectives can inform the priorities, 
goals, and conduct of research and the ultimate value new diagnostic tools and 
therapies can deliver to patients.
The CIOMS/WHO guidelines also reflect the importance of engaging patient 
communities in the governance of research. Patients have valuable perspectives 
on both the potential value of research and the acceptability of associated physical 
and privacy risks. Patients also have perspectives on how consent documentation 
can meaningfully communicate the nature of research, its benefits and risks, 
and the safeguards in place to limit risks. Patient involvement in the governance 
of research can supplement the efforts of RECs to ensure the ethical conduct of 
research. There is a spectrum of patient involvement approaches, from feedback 
through surveys or workshops, to advisory boards, to formal leadership roles 
within research, to patient-led initiatives where patient groups decide when and 
how to engage experts [44].
Patient involvement can involve important costs and potential delays for 
research. There is a risk that involvement initiatives successful in specific research 
and community contexts are extrapolated by policy-makers or oversight bodies into 
generic ethical requirements [45]. Researchers alone cannot be expected to bear the 
financial and administrative burden of patient involvement without appropriate 
support from funding agencies and institutions. Imposing specific forms of involve-
ment as an ethical requirement may also encourage a compliance mentality where 
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researchers want to get it out of the way rather than developing meaningful com-
munity and partnership with patients. Systemic barriers and negative perceptions 
can discourage patients from meaningfully engaging with researchers. Patients are 
already dealing with the burden of living with a disease and potentially also the 
burden of participating in research. It may therefore be difficult for them to visit 
research sites in order to participate in unpaid involvement activities. Patients may 
also have negative perceptions that they will not actually be listened to [42]. Some 
critics have highlighted that patient involvement is usually designed to advance an 
institutional agenda rather than truly give a voice to all patients [45]. Involvement 
activities do not necessarily mean that patients have significant decision-making 
power. Researchers may preferentially seek to engage with patients who have 
considerable experience as research participants, as well as experience with research 
involvement activities, which may reduce opportunities to hear other voices.
The organizational governance of patient advocacy groups is often informal, 
which raises concerns about democratic representation and managing conflicts 
of interest. There can often be major differences of opinion within a patient com-
munity. Some patient advocacy groups receive significant financial support from 
pharmaceutical companies and may not have formal processes in place for declaring 
and managing these conflicts [46]. Patient involvement challenges may be exacer-
bated in rare disease contexts. Patient involvement for rare disease may be difficult 
for the same reasons that doing research on rare disease is difficult. Patients may 
be small in number, geographically dispersed, and may have very heterogeneous 
experiences with the disease. This makes it hard to survey patients about their views 
on research. Many patients with rare disease struggle to even receive an accurate 
diagnosis, which may affect their ability to identify with and organize a specific 
community in the first place.
Patients are also increasingly engaged in the governance of biobanking and data 
sharing. YOURDNAYOURSAY is an interactive, international, online survey explor-
ing public perspectives about the international sharing of genomic and health-
related data. The results of the survey address public fears over potential harms, 
public willingness to release their data, and how trust differs between organizations 
[47, 48]. A European survey specific to rare disease patients found they were sup-
portive of data sharing to improve research and health care, as long as steps were 
taken to provide individual patients with meaningful choices, to protect patient 
privacy, and to provide patients with transparent information about how their data 
are shared and used [49]. Patients can also be engaged in the design of governance 
documents for biobanks and databases, such as access policies, privacy safeguards, 
and consent forms (see previous sections). This involvement can provide assurances 
that governance strikes an appropriate balance between openness and promotion 
of science with protection of participant privacy. In many cases, patients may 
be highly supportive of greater openness in research and their perspectives may 
serve as a counterweight to overly protective stances by oversight bodies like RECs. 
Patients may also participate directly on biobank access committees, influencing 
decisions about which researchers receive samples and data, for which research 
projects.
Patient involvement in the governance of biobanking and data sharing can raise 
tensions between community control and scientific openness. In particular, the 
value of biobanks and data sharing is often dependent on their integration into 
networks allowing integration of multiple resources to increase statistical power. 
This is particularly true for rare disease. There is a recognized need for harmonized 
ethical and legal governance of biobanks and databases to enable such integration. 
One potential solution is for involvement activities to address the importance of 
harmonization with patient groups, to make sure this value is taken into account in 
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the co-development of governance [50]. Another potential solution is to develop 
more concerted public involvement efforts in the development of international 
standards for biobank and data sharing governance.
6. Conclusion
Rare disease research continues to be hampered by lack of academic and com-
mercial incentives and practical barriers to conducting research involving small, 
geographically dispersed populations. This results in limited understanding of rare 
diseases, delayed diagnoses and a lack of therapeutic options for patients. There 
is hope that international biobank networks and data sharing can improve care 
and advance research into rare disease. Research ethics concerns about protecting 
patient privacy, enabling individuals to make informed decisions, and involving 
patients in governance deserve concerted and nuanced attention in these contexts. 
Standard governance approaches may need to be re-calibrated for rare disease 
contexts, given the necessity of openness, high unmet need, and the willingness of 
many rare disease patients to contribute to biobanks and databases, despite minor 
privacy risks. This is not to say that rare patients do not care about privacy or about 
being offered meaningful choices. Involving patients in the governance of biobanks 
and data sharing, while appropriately highlighting the importance of international 
collaboration, can help to ensure these activities ultimately improve the prospects 
of those with rare disease.
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